Menu
Search
|

Menu

Close
X

TG Therapeutics Inc TGTX.OQ (NASDAQ Stock Exchange Capital Market)

11.45 USD
-0.55 (-4.58%)
As of Jul 18
chart
Previous Close 12.00
Open 12.05
Volume 331,074
3m Avg Volume 247,175
Today’s High 12.05
Today’s Low 11.35
52 Week High 17.30
52 Week Low 7.25
Shares Outstanding (mil) 68.84
Market Capitalization (mil) 846.68
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.588
FY17
-1.917
FY16
-1.594
FY15
-1.383
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
5,555.65
5.73
Price to Book (MRQ)
vs sector
10.74
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.20
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-129.83
14.61
Return on Equity (TTM)
vs sector
-133.51
16.34

EXECUTIVE LEADERSHIP

Michael Weiss
Executive Chairman of the Board, President, Chief Executive Officer, Since 2011
Salary: $375,000.00
Bonus: --
Sean Power
Chief Financial Officer, Treasurer, Corporate Secretary, Since 2011
Salary: $300,000.00
Bonus: --
Adam Waldman
Chief Commercial Officer, Since 2018
Salary: --
Bonus: --
Laurence Charney
Independent Director, Since 2012
Salary: --
Bonus: --
Yann Echelard
Independent Director, Since 2012
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2 Gansevoort St Fl 9
NEW YORK   NY   10014-1667

Phone: +1212.5544484

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.

SPONSORED STORIES